Juno Therapeutics Raises $120M in Series A Funding

juno therapeuticsJuno Therapeutics Inc., a Seattle, WA-based clinical stage company that develops cancer immunotherapy products, has been founded with a $120m Series A funding.

Initial backers include ARCH Venture Partners and the Alaska Permanent Fund, through a partnership managed by Crestline Investors.

Launched by the Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children’s Research Institute, and led by Co-founder and Chief Executive Officer Hans Bishop, a longtime biotech industry veteran, Juno Therapeutics is developing technology to reprogram immune cell called T lymphocytes (T cells) to recognize cancer cells for a precision immunologic attack.

The company’s other co-founders are:
– Larry Corey, M.D., president and director of Fred Hutchinson Cancer Research Center;
– Richard Klausner, M.D., former director of the National Cancer Institute; and
– Robert Nelsen, co-founder and a managing director of ARCH Venture Partners.



Join the discussion